Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the reason for pop:
AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer's Disease
20.February 2019 13:39 CET
English
Study complements ongoing trial in the prodromal to mild population
Lausanne, Switzerland, February 20, 2019 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Genentech, a member of the Roche Group, is recruiting patients for a second Phase 2 trial for an anti-Tau monoclonal antibody, known as MTAU9937A, RO7105705, in moderate Alzheimer's disease (AD). The same antibody, RG6100 (MTAU9937A, RO7105705), also is being studied by Genentech in a separate Phase 2 trial to evaluate its efficacy and safety in patients with prodromal-to-mild Alzheimer's disease. This anti-Tau monoclonal antibody was discovered and humanized as part of AC Immune's collaboration with Genentech.
Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: "We are highly encouraged that Genentech is broadening its clinical evaluation of our anti-Tau antibody. Interest in targeting Tau was also recently demonstrated by our newest partnership with Eli Lilly, announced in early January, to develop our small molecule Tau MorphomerTM to treat Alzheimer's. These projects illustrate AC Immune's scientific leadership in the field and are an important part of our broad portfolio of three product candidates in Phase 2 clinical testing, complementary diagnostics in clinical development, a robust early-stage pipeline and an increasingly visible focus on early projects targeting neuro-orphan and neuro-inflammation indications."
The trial, posted here, is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of MTAU9937A, RO7105705 in an estimated 260 patients with moderate AD dementia. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period. The primary endpoints are change from baseline to Week 49 in cognitive function as measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 11-item version (ADAS-Cog11) and change from baseline to Week 49 in functional capacities as measured by the Alzheimer's Disease Cooperative Study-Daily Living Inventory (ADCS-ADL).
This anti-Tau monoclonal antibody is part of the strategic collaboration with Genentech entered into in 2012 for the research, development and commercialization of monoclonal humanized antibodies against Tau protein. RO7105705 is a humanized anti-Tau monoclonal antibody with a high specificity for pathological Tau, designed to intercept the cell-to-cell spread of pathological Tau in the extracellular space of the brain.
Tau pathology spreads with a characteristic spatiotemporal pattern throughout the brain, coinciding with both clinical symptoms and disease progression in AD. Slowing the propagation of tau pathology may therefore slow disease progression and reduce cognitive decline, and anti-tau therapies have shown promise in slowing the progression of tau pathology in animal models of tauopathy.
AC Immune has several product candidates addressing the Tau approach, including: ACI-35, an anti-pTau vaccine partnered with Janssen Pharmaceuticals, currently in a Phase 1b/2a trial, a small molecule Tau MorphomerTM, partnered with Eli Lilly and Company, that is scheduled to enter Phase 1 in 2019; and a Tau imaging agent, partnered with Life Molecular Imaging (formerly Piramal Imaging), currently in Phase 2 clinical testing.
Released today by Zacks. Any ESP (earnings surprise predictor) reading of greater than 0 implies that there is greater than a 70% probability that there will be an earnings surprise to the 'upside'. Earnings are scheduled to be released on 3/19/19. Hence the pop in PPS today!!!
Stocks to Consider (by Zacks)
Here are a few medical stocks worth considering with the right combination of elements to beat on earnings in the upcoming quarterly releases.
AC Immune SA ACIU has an Earnings ESP of +86.79% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
ACIU~Dr. Pfeifer continued, “We remain committed to our on-going pre-clinical and clinical candidates targeting Tau and neuro-inflammation to treat Alzheimer’s disease, neuro-orphan diseases and Parkinson’s disease, which are partnered with five leading pharmaceutical partners, including Roche’s subsidiary Genentech.”
* * $ACIU Video Chart 01-30-2019 * *
Link to Video - click here to watch the technical chart video
ACIU~~4.34 and going,100% bounce easy coming from the bottom 3.25
ACIU~~3.75 ,-65%% ,bounce time
AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission To...
* Grant supports next step in development of potentially first alpha-synuclein PET tracer for Parkinson's disease
* Start of first-in-human study of current lead is scheduled for Q1 2019
* Follow-up grant marks longstanding collaboration with The Michael J. Fox Foundation (MJFF)
Lausanne, Switzerland, November 15, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it has been awarded a follow-up grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). In 2015 AC°Immune received a research grant from the MJFF to support the development of a Parkinson's-specific diagnostic agent. Following a grant extension in 2017, the new grant is an acknowledgement of the progress AC Immune has made in this program. This grant aims to facilitate the execution of a first-in-human study for a potential alpha-synuclein PET tracer with the current lead compound. The study will commence in Q1 of 2019. The amount of the grant has not been disclosed.
Prof. Andrea Pfeifer, CEO of AC Immune, said: "We are honored to receive, for the third time, funding from the prestigious Michael J. Fox Foundation underlining our collaboration and dedication to find earlier and more accurate tools for the diagnosis of Parkinson's disease. This new follow-up grant further validates AC°Immune's leading expertise in the pathology of misfolded proteins and our vision to become a global leader in precision medicine of neurodegenerative diseases."
https://ih.advfn.com/p.php?pid=nmona&article=78695919
WOW! 3 consecutive prs recently. This is getting more eyes watching!
Its not a surprise when one day AC Immune will be acquired, in my opinion.
regards
AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome
* Start of Phase 2 trial with ACI-24 in patients with mild Alzheimer's disease; first patient enrolled
* Recruitment completed for high-dose cohort of Phase 1b study with ACI-24 for Abeta-related cognitive decline in individuals with Down Syndrome
ACI-24 Vaccine for Alzheimer's Disease
AC Immune has started the Phase 2 study with ACI-24 in patients with mild Alzheimer's disease (AD). The aim of this double-blind, randomized, placebo-controlled study with an adaptive design is to assess the safety, tolerability, immunogenicity, target engagement, biomarkers and clinical efficacy of ACI-24. The trial will seek to confirm the positive trends on Abeta PET* imaging and clinical measurement (CDR-SB°) of the previous Phase 1 safety study. The Phase 2 trial will be conducted in several European countries and the first patients have been screened.
ACI-24 in Down Syndrome
AC Immune has completed recruitment for the high-dose cohort of the ACI-24 Phase°1b study for the treatment of Alzheimer's disease-like characteristics in adults with Down Syndrome (DS), a condition affecting approximately one in 700 newborns. The first low-dose and the second high-dose cohorts have been fully recruited in August 2017 and in July 2018 respectively, and interim results of the low dose cohort are expected later in 2018. In addition to cognitive dysfunction beginning in childhood, individuals with DS are genetically-predisposed to develop Abeta-related cognitive decline at a much younger age and with much greater probability than the general population.
http://ir.acimmune.com/phoenix.zhtml?c=254264&p=irol-news&nyo=0
ACIU is getting back on track looks like,up nicely today(9%).
Bought some @9.75 today.Odd that it was nicely up above $10 for most part of the day,then trailed down.Low floater,wide Bid/Ask gaps,hopefully will do well when volume comes in.
You're right. Oversold! on Positive data even??? Truly laughable! AC Immune and partners Genentech/Roche is in full steam in the race to treat and prevent AD. https://www.acimmune.com/ <<< DDs here!
Is this 2 day drop overdone?It's now much below the recent $11.75 share offering price(had thought that would've been the floor).It had probably gone up on the hype,but isn't this drop looking overdone,that too when it's not on company-specific news,but just in sympathy with BIIB?
Would like to hear thoughts of those who've followed this company ,the science,and the Alzheimer's disease group.Thanks
WOW! Awesome move today! Next week's sentiment should be interesting considering the upcoming company/partners presentation in Chicago. More eyes are noticing this gem! THE RACE TO TREAT/PREVENT ALZHEIMER'S DISEASE IS ON!!!
AC Immune (NASDAQ: ACIU) MILESTONES/HISTORY
2018
Genentech milestone payment 3 (anti-Tau antibody)
2017
Essex Bio-Technology research collaboration for neurodegenerative diseases and neuroinflammation
2016
INITIAL PUBLIC OFFERING (IPO) on NASDAQ
2016
Genentech milestone payment 2 (anti-Tau antibody)
2016
Biogen research and development collaboration for diagnostics in neurodegenerative diseases
2015
Nestlé Institute of Health Science research collaboration for Tau diagnostic assay
2015
Genentech milestone payment 3 (crenezumab)
2015
Genentech milestone payment 1 (anti-Tau antibody)
2015
Janssen Pharmaceuticals licensing agreement for anti-Tau therapeutic vaccine ($509 million)
2014
Piramal Imaging licensing agreement for anti-Tau diagnostic (significant value)
2012
Genentech licensing agreements for anti-Tau antibody ($418 million)
2011
Genentech milestone payment 2 (crenezumab)
2009
E&Y Entrepreneur of the Year
WEF Technology Pioneer
2009
Bayer Schering collaboration for brain imaging taken over by Piramal Imaging
2008
Genentech milestone payment 1 (crenezumab)
2006
Genentech licensing agreements for anti-Abeta antibody ($300 million)
2003
Foundation of AC Immune
https://www.acimmune.com/en/history/
Awesome move last Friday. Yes, been quiet for long time. Good to see somebody around. I thought I'm alone here. lol
Stealth mode indeed. Not even “profiled” as a trade by Claytrader after the 38% spike on 7/6/18. Very quiet around here as well.
This is very well kept in stealth-mode. Great robust pipeline and partnerships. A potential M&A target, IMO.
https://www.acimmune.com/en/pipeline-overview/
lovin' that swiss :), patiently waiting to skyrocket!
Long&Strong
Awesome news today!
AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's diseas...
>>> First potential PET tracer for Parkinson's disease
>>> First in human study is scheduled for the second half of 2018
>>> AC Immune's lead compound is highly selective for alpha-synuclein - a key protein in Parkinson's disease pathology
This next generation tracer was discovered using the company's proprietary MorphomerTM chemistry technology platform. AC Immune has been successfully collaborating on this program with Biogen since April 2016. The companies will continue to further research, develop and clinically validate this alpha-synuclein PET tracer that will be used as an imaging biomarker for Parkinson's disease with an aim to enable the clinical development of new disease-modifying therapies. This project from AC Immune is being supported by The Michael J. Fox Foundation for Parkinson's Research (MJFF).
https://ih.advfn.com/p.php?pid=nmona&article=76951663
Good NEWS! Today...AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD'S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIM...
https://finance.yahoo.com/news/ac-immune-completes-recruitment-low-100553627.html
Exciting times ahead.
gotta luv swiss :)
We are approaching the lowest price for ACIU for the year! Have the fundamentals really changed that much? I'm ready for the spigot to be opened on the pipeline! Go ACIU!
End of quiet period....should be interesting. Just took a stater position at $9.98
I got my Long Term position of 1000 shares here today. This newly-IPO biotech company has great pipeline with established partnership among the best companies in the pharma/biotech industry. I'm not surprise when this gets acquired in a short period of time, IMHO.
Good Luck
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
91
|
Created
|
09/26/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |